Topical SR-T100 effective, safe for actinic keratosis
SR-T100, a topical Solanum undatum extract containing solamargine as the active ingredient, appears to be safe and effective for actinic keratosis (AK), according to a recent Taiwan phase III trial.
The rate of overall complete AK clearance was nonsignificantly greater in the SR-T100 gel (n=76; mean age 76.6±88 years; 67.1 percent male) than in the vehicle control group (n=36; mean age 76.7±9.2 years; 61.1 percent male; 32.4 percent vs 17.1 percent; p=0.111). The odds of overall clearance were likewise nonsignificantly better in the SR-T100 group (odds ratio, 2.14; 95 percent CI, 0.74-6.17).
In comparison, the rate of complete clearance was significantly better when analysis was confined to the arm/chest (52.6 percent vs 0 percent; p=0.010).
The SR-T100 gel appeared to be significantly better than the vehicle control when it came to the secondary outcome of partial clearance. There were more patients in the SR-T100 vs control group who experienced ≥75 percent clearance (71.8 percent vs 37.1 percent; p<0.001).
Partial clearance of ≥80 percent, ≥85 percent, ≥90 percent and ≥95 percent were also significantly more common in the SR-T100 vs vehicle control treatments.
The rate of at least one adverse event (55.3 percent vs 51.4 percent) and serious adverse events (13.2 percent vs 13.5 percent) were comparable between the two treatments. Local skin reactions such as erythema (43.4 percent vs 18.9 percent), burning/stinging (36.8 percent vs 8.1 percent) and erosion (34.2 percent vs 5.4 percent) were all more common in the SR-T100 group, and severity of these reactions were correlated positively with degree of treatment response.
“SR-T100, because of its favourable local skin reaction profile compared to other currently available treatment option[s], is a better topical agent for long-term field therapy for AK,” said researchers.